CASI PHARMACEUTICALS INC (CASI) Forecast, Price Target & Analyst Ratings
NASDAQ:CASI • KYG1933S1012
0.2075 USD
-0.59 (-74.06%)
At close: Feb 25, 2026
0.28 USD
+0.07 (+34.94%)
After Hours: 2/25/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CASI PHARMACEUTICALS INC (CASI).
Forecast Snapshot
Consensus Price Target
$4.08
+ 1,866.27% Upside
Next Earnings Forecast
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.37
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.08
Upside
+ 1,866.27%
From current price of $0.21 to mean target of $4.08, Based on 7 analyst forecasts
Low
$4.04
Median
$4.08
High
$4.20
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 1866.27% is expected in the next year compared to the current price of 0.2075.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
CASI was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CASI.
In the previous month the buy percentage consensus was at a similar level.
CASI was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2022-11-16 | BTIG | Maintains | Buy |
| 2022-11-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy |
| 2022-06-03 | BTIG | Maintains | Buy |
| 2022-05-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-18 | BTIG | Initiate | Buy |
| 2021-05-14 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-26 | Mizuho | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 30, 2026
PeriodQ4 / 2025
EPS Estimate-$0.37
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q40.00%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
CASI is expected to report earnings on 3/30/2026. The consensus EPS estimate for the next earnings is -0.37 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 43.107M 42.89% | 33.879M -21.41% | 28.537M -15.77% | 13.76M -51.78% | -100.00% | 11.399M | 31.253M 174.17% | 47.46M 51.86% | 61.413M 29.40% | |||
| EBITDA YoY % growth | -24.069M 28.08% | -21.539M 10.51% | -32.081M -48.94% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -26.491M 24.92% | -25.28M 4.57% | -34.412M -36.12% | -38.861M -12.93% | -25.221M 35.10% | -27.04M -7.22% | -29.242M -8.14% | -21.262M 27.29% | -5.995M 71.81% | -3.891M 35.09% | 5.128M 231.78% | |
| Operating Margin | -61.45% | -74.62% | -120.59% | -282.42% | N/A | N/A | N/A | -186.52% | -19.18% | -8.20% | 8.35% | |
| EPS YoY % growth | -3.40 -25.93% | -2.02 40.59% | N/A -29.27% | -2.63 -0.78% | -1.44 45.35% | -1.42 1.42% | 1.32 192.81% | 1.59 20.93% | 1.83 14.74% | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 40.00% | -0.37 46.78% | -0.36 58.49% | -0.36 46.72% | -0.36 2.78% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.036M 20.09% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
8.80%
EPS Next 5 Year
21.53%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-25.99%
Revenue Next 5 Year
-14.87%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CASI PHARMACEUTICALS INC / CASI Forecast FAQ
What do analysts expect the price target to be for CASI PHARMACEUTICALS INC (CASI)?
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 1866.27% is expected in the next year compared to the current price of 0.2075.
When does CASI PHARMACEUTICALS INC (CASI) report earnings?
CASI PHARMACEUTICALS INC (CASI) will report earnings on 2026-03-30, before the market open.
Can you provide the consensus estimates for CASI PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of CASI PHARMACEUTICALS INC (CASI) is -0.37 USD and the consensus revenue estimate is 0 USD.
Can you provide the expected long term growth rate for CASI PHARMACEUTICALS INC stock?
The expected long term growth rate for CASI PHARMACEUTICALS INC (CASI) is -25.99%.